SAN DIEGO, Oct. 31, 2017 -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) has scheduled a conference call to review its third quarter 2017 financial results and provide a business update.
The call is scheduled for 2:00 p.m. US PST on Tuesday, November 7, 2017 (which is 9:00 a.m. AEDT on Wednesday, 8 November 2017) and may be accessed within the United States and Canada by dialing 1-877-312-5413 five minutes prior to the scheduled start time. Callers in Australia may access the call toll-free by dialing 1800 005 989. The conference ID is 1289896 for all locations.
If you reside outside of the United States, Canada, or Australia, or if you prefer to access the call through our website, please visit “Events & Presentations” under the “Investors” section of our website at www.revamedical.com, and click on the “listen to webcast” link. A live webcast of the call will also be available on our website.
About REVA Medical
REVA Medical is a medical device company focused on the development and commercialization of bioresorbable polymer technologies for vascular applications. The Company’s lead product, the Fantom bioresorbable scaffold, received European CE Mark on April 3, 2017 for the treatment of coronary artery disease. REVA is located in San Diego, California, USA and employs over 50 people in the U.S. and Europe.
About Fantom®
Fantom is a sirolimus-eluting bioresorbable scaffold (BRS) developed as an alternative to metallic stents for the treatment of coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, and then disappear (or “resorb”) from the body over a period of time. This resorption is intended to allow the return of natural movement and function of the artery. Fantom is the only bioresorbable scaffold made from Tyrocore™, REVA’s proprietary tyrosine-derived polymer designed specifically for vascular scaffold applications. Tyrocore is inherently radiopaque, making Fantom the first and only BRS that is visible under fluoroscopy. Fantom is designed with thin struts while maintaining strength and with distinct ease-of-use features such as expansion with one continuous inflation.
| United States | Australia | Australia | |
| Investor & Media Enquiries: | Investor Enquiries: | Media Enquiries: | |
| REVA Medical, Inc. | Inteq Limited | Buchan Consulting | |
| Brandi Roberts | Kim Jacobs | Rebecca Wilson | |
| Chief Financial Officer | +61 438 217 279 | +61 3 9866 4722 | |
| +1 858-966-3003 | Andrew Cohen | ||
| Cheryl Liberatore | +61 408 333 452 | ||
| Director, Communications | |||
| +1 858-966-3045 | |||
| [email protected] |


Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 



